To avoid unwanted side effects due to oral steroids, it is best to have a good post-cycle therapy (PCT) plan. Nolvadex ...

Clinically Inspired Gut-Skin Axis Supplement Prime Biome Faces Real Consumer Feedback and Scientific Scrutiny—Here’s What the ...

PURCHASE, NY, April 16, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release first quarter 2025 results on Wednesday, April 30, ...

The grant to Dr. Shah provides for the issuance of 191,624 stock options. Additionally, the grants to the two employees provide for the issuance of an aggregate of 21,000 stock options. Each grant ...

The new non-executive employee received an option to purchase 105,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $1.54, which was the ...

VIMKUNYA was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 6,7. Bavarian Nordic has also filed for approval of the vaccine in the United Kingdom ...

WEST PALM BEACH, FL, April 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”) announces that it has filed its Annual Report on Form 10-K on April 15, 2025.

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido ® is a registered ...

Our roadmap for the next two to four years includes strategic entry into emerging markets where Biosidus has established partnerships, with a long-term goal of reaching Europe and the United States.

The RSU awards, stock option and PSU award were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635 (c) (4) under ...

BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Eascra Biotech research will be aboard SpaceX 32, scheduled to launch in April, continuing the startup’s ongoing work producing their JBNps (Janus Base ...

Revenue increased by 2.0% to $54.43 million in FY 2024, from $53.38 million in the prior year, driven primarily by sustained organic growth and continued contributions from prior acquisitions. Gross ...